Advanced T cell therapy

Advanced T cell therapy - Major publications

• Ablation of FAS confers allogeneic CD3^- CAR T cells with resistance to rejection by T cells and natural killer cells. Menegatti S, Lopez-Cobo S, Sutra Del Galy A, Fuentealba J, Silva L, Perrin L, Heurtebise-Chrétien S, Pottez-Jouatte V, Darbois A, Burgdorf N, Privat AL, Simon A, Laprie-Sentenac M, Saitakis M, Wick B, Webber BR, Moriarity BS, Lantz O, Amigorena S, Menger L. Nat Biomed Eng. 2024 Nov 18. doi: 10.1038/s41551-024-01282-8.
• Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4⁺ CAR T-cell antitumor activity.  Boulch M, Cazaux M, Cuffel A, Guerin MV, Garcia Z, Alonso R, Lemaître F, Beer A, Corre B, Menger L, Grandjean CL, Morin F, Thieblemont C, Caillat-Zucman S, Bousso P. Nat Cancer. 2023 Jul;4(7):968-983. doi: 10.1038/s43018-023-00570-7.
• Optimized protocol to generate genome-wide inactivated Cas9-expressing murine T cells. Laprie-Sentenac M, Cretet-Rodeschini C, Menger L. STAR Protoc. 2023 Mar 17;4(1):101922. doi: 10.1016/j.xpro.2022.101922.
• Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma. Costa A, Thirant C, Kramdi A, Pierre-Eugène C, Louis-Brennetot C, Blanchard O, Surdez D, Gruel N, Lapouble E, Pierron G, Sitbon D, Brisse H, Gauthier A, Fréneaux P, Bohec M, Raynal V, Baulande S, Leclere R, Champenois G, Nicolas A, Meseure D, Bellini A, Marabelle A, Geoerger B, Mechta-Grigoriou F, Schleiermacher G, Menger L, Delattre O, Janoueix-Lerosey I. J Immunother Cancer. 2022 Aug;10(8):e004807. doi: 10.1136/jitc-2022-004807.
• Tissue-resident FOLR2⁺ macrophages associate with CD8⁺ T cell infiltration in human breast cancer. Nalio Ramos R, Missolo-Koussou Y, Gerber-Ferder Y, Bromley CP, Bugatti M, Núñez NG, Tosello Boari J, Richer W, Menger L, Denizeau J, Sedlik C, Caudana P, Kotsias F, Niborski LL, Viel S, Bohec M, Lameiras S, Baulande S, Lesage L, Nicolas A, Meseure D, Vincent-Salomon A, Reyal F, Dutertre CA, Ginhoux F, Vimeux L, Donnadieu E, Buttard B, Galon J, Zelenay S, Vermi W, Guermonprez P, Piaggio E, Helft J. Cell. 2022 Mar 31;185(7):1189-1207.e25. doi: 10.1016/j.cell.2022.02.021.
• In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4⁺ T_H1 cell response.  Sutra Del Galy A, Menegatti S, Fuentealba J, Lucibello F, Perrin L, Helft J, Darbois A, Saitakis M, Tosello J, Rookhuizen D, Deloger M, Gestraud P, Socié G, Amigorena S, Lantz O, Menger L. Sci Immunol. 2021 Dec 3;6(66):eabe8219. doi: 10.1126/sciimmunol.abe8219.
• Methods to edit T cells for cancer immunotherapy.  Lucibello F, Menegatti S, Menger L. Methods Enzymol. 2020;631:107-135. doi: 10.1016/bs.mie.2019.05.048.
• TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA. Cancer Res. 2016 Apr 15;76(8):2087-93. doi: 10.1158/0008-5472.CAN-15-3352.
• Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Menger L, Śledzińska A, Bergerhoff K, Peggs KS, Quezada SA. Mol Oncol. 2015 Dec;9(10):1936-65. doi: 10.1016/j.molonc.2015.10.008.
• TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY, Smith J, Pule M, Moss P, Riddell SR, Quezada SA, Peggs KS. Blood. 2015 Dec 24;126(26):2781-9. doi: 10.1182/blood-2015-08-664755. Epub 2015 Oct 27.
• Crosstalk between ER stress and immunogenic cell death. Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, Galluzzi L, Kroemer G, Zitvogel L. Cytokine Growth Factor Rev. 2013 Aug;24(4):311-8. doi: 10.1016/j.cytogfr.2013.05.001.
• Trial watch: Cardiac glycosides and cancer therapy. Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Oncoimmunology. 2013 Feb 1;2(2):e23082. doi: 10.4161/onci.23082.
• Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, Modjtahedi N, Galluzzi L, André F, Zitvogel L, Kepp O, Kroemer G. Sci Transl Med. 2012 Jul 18;4(143):143ra99. doi: 10.1126/scitranslmed.3003807